secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2023-12-28T23:59:59+00:00
Accession:  0001628280-23-042817
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics executes 1-for-240 reverse stock split to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Reverse split effective 5:00 PM ET Dec 28, 2023; shares trade split-adjusted Dec 29 under AVTX.
- Shares outstanding reduced from ~192.4M to ~801,611; fractional shares rounded up to whole share.
- Split raises per-share price to satisfy Nasdaq Capital Market minimum bid price rule.
- No change to authorized shares or par value; options/warrants adjusted proportionally.
- New CUSIP 05338F306; Equiniti Trust Company acting as exchange agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023042817/0001628280-23-042817-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023042817/avtx-20231228.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-042817

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer